Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.37 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1741229 | 0.80 | CTH (0.38) | GRIK1TDP1ALDH1A1LMNAMAPT | |
| SCHEMBL7783653 | 0.78 | — | — | |
| SCHEMBL1263396 | 0.74 | — | — | |
| SCHEMBL25748 | 0.74 | — | — | |
| SCHEMBL28963615 | 0.73 | USP2 (0.39) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL3179343 | 0.72 | LDHA (0.37) | TDP1ALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL27422304 | 0.72 | GAA (0.46) | CYP1A2ALDH1A1 | |
| SCHEMBL16005555 | 0.72 | — | — | |
| SCHEMBL8828900 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL1728563 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295632-A1 | METHODS OF CONTROLLING RED BLOOD CELL PRODUCTION | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-09-21 | — | — | US | claimed |
| US-20190270992-A1 | METHODS OF CONTROLLING RED BLOOD CELL PRODUCTION | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2019-09-05 | — | — | US | claimed |
| US-20230295632-A1 | METHODS OF CONTROLLING RED BLOOD CELL PRODUCTION | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-09-21 | — | — | US | disclosed |
| US-20190270992-A1 | METHODS OF CONTROLLING RED BLOOD CELL PRODUCTION | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2019-09-05 | — | — | US | disclosed |
| EP-1348024-B1 | DESIGN AND USE OF ADVANCED ZINC CHELATING PEPTIDES TO REGULATE MATRIX METALLOPROTEINASES | KIMBERLY CLARK CO (US) | 2006-10-11 | — | — | EP | disclosed |
| US-7041787-B2 | Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1348024-A2 | DESIGN AND USE OF ADVANCED ZINC CHELATING PEPTIDES TO REGULATE MATRIX METALLOPROTEINASES | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030073808-A1 | Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases | AVENT, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002053173-A2 | DESIGN AND USE OF ADVANCED ZINC CHELATING PEPTIDES TO REGULATE MATRIX METALLOPROTEINASES | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073808-A1 | Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases | TIMP3, MMP12, MMP16 | GRM8 3996/4885GRM6 3390/4885GRIN2D 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.